205 related articles for article (PubMed ID: 33740539)
21. The ATM and Rad3-Related (ATR) Protein Kinase Pathway Is Activated by Herpes Simplex Virus 1 and Required for Efficient Viral Replication.
Edwards TG; Bloom DC; Fisher C
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263259
[TBL] [Abstract][Full Text] [Related]
22. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
23. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
Walton MI; Eve PD; Hayes A; Valenti M; De Haven Brandon A; Box G; Boxall KJ; Aherne GW; Eccles SA; Raynaud FI; Williams DH; Reader JC; Collins I; Garrett MD
Mol Cancer Ther; 2010 Jan; 9(1):89-100. PubMed ID: 20053762
[TBL] [Abstract][Full Text] [Related]
24. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
Drápela S; Khirsariya P; van Weerden WM; Fedr R; Suchánková T; Búzová D; Červený J; Hampl A; Puhr M; Watson WR; Culig Z; Krejčí L; Paruch K; Souček K
Mol Oncol; 2020 Oct; 14(10):2487-2503. PubMed ID: 32579780
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of cells to ATR and CHK1 inhibitors requires hyperactivation of CDK2 rather than endogenous replication stress or ATM dysfunction.
Ditano JP; Donahue KL; Tafe LJ; McCleery CF; Eastman A
Sci Rep; 2021 Mar; 11(1):7077. PubMed ID: 33782497
[TBL] [Abstract][Full Text] [Related]
26. ATR/CHK1 inhibitors and cancer therapy.
Qiu Z; Oleinick NL; Zhang J
Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
Parsels LA; Morgan MA; Tanska DM; Parsels JD; Palmer BD; Booth RJ; Denny WA; Canman CE; Kraker AJ; Lawrence TS; Maybaum J
Mol Cancer Ther; 2009 Jan; 8(1):45-54. PubMed ID: 19139112
[TBL] [Abstract][Full Text] [Related]
28. Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.
Blackwood E; Epler J; Yen I; Flagella M; O'Brien T; Evangelista M; Schmidt S; Xiao Y; Choi J; Kowanetz K; Ramiscal J; Wong K; Jakubiak D; Yee S; Cain G; Gazzard L; Williams K; Halladay J; Jackson PK; Malek S
Mol Cancer Ther; 2013 Oct; 12(10):1968-80. PubMed ID: 23873850
[TBL] [Abstract][Full Text] [Related]
29. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
30. Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.
Dai CH; Wang Y; Chen P; Jiang Q; Lan T; Li MY; Su JY; Wu Y; Li J
Sci Rep; 2017 Nov; 7(1):15031. PubMed ID: 29118324
[TBL] [Abstract][Full Text] [Related]
31. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
[TBL] [Abstract][Full Text] [Related]
32. Modification of tumour cell metabolism modulates sensitivity to Chk1 inhibitor-induced DNA damage.
Massey AJ
Sci Rep; 2017 Jan; 7():40778. PubMed ID: 28106079
[TBL] [Abstract][Full Text] [Related]
33. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.
Zhang YW; Jones TL; Martin SE; Caplen NJ; Pommier Y
J Biol Chem; 2009 Jul; 284(27):18085-95. PubMed ID: 19416980
[TBL] [Abstract][Full Text] [Related]
34. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
[TBL] [Abstract][Full Text] [Related]
35. Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
Xiao Y; Ramiscal J; Kowanetz K; Del Nagro C; Malek S; Evangelista M; Blackwood E; Jackson PK; O'Brien T
Mol Cancer Ther; 2013 Nov; 12(11):2285-95. PubMed ID: 24038068
[TBL] [Abstract][Full Text] [Related]
36. Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells.
Isono M; Okubo K; Asano T; Sato A
PLoS One; 2022; 17(4):e0266476. PubMed ID: 35413091
[TBL] [Abstract][Full Text] [Related]
37. γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.
Rawlinson R; Massey AJ
BMC Cancer; 2014 Jul; 14():483. PubMed ID: 24996846
[TBL] [Abstract][Full Text] [Related]
38. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
Parsels LA; Qian Y; Tanska DM; Gross M; Zhao L; Hassan MC; Arumugarajah S; Parsels JD; Hylander-Gans L; Simeone DM; Morosini D; Brown JL; Zabludoff SD; Maybaum J; Lawrence TS; Morgan MA
Clin Cancer Res; 2011 Jun; 17(11):3706-15. PubMed ID: 21482692
[TBL] [Abstract][Full Text] [Related]
39. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
Barnard D; Diaz HB; Burke T; Donoho G; Beckmann R; Jones B; Barda D; King C; Marshall M
Invest New Drugs; 2016 Feb; 34(1):49-60. PubMed ID: 26612134
[TBL] [Abstract][Full Text] [Related]
40. Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.
Nieto-Jimenez C; Alcaraz-Sanabria A; Martinez-Canales S; Corrales-Sanchez V; Montero JC; Burgos M; Nuncia-Cantarero M; Pandiella A; Galan-Moya EM; Ocaña A
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]